Drug profile

The FDA adverse-event record for Ofloxacin Ophthalmic

10 adverse-event reports submitted to the FDA Center for Veterinary Medicine reference Ofloxacin Ophthalmic. See the species affected, top reactions, and outcomes below.

10
adverse-event reports
10.0%
death-coded share
Dog
most-reported species
2
Disorientation - top reaction
Verify with FDA CVM →
Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
10
Total Reports
1
Deaths Reported
10.0%
Death Rate

Active Ingredients

Ofloxacin Ophthalmic

Administration Routes

IntraocularOphthalmicUnknownTopical

Species Affected

Dog 8
Cat 2

Most Affected Breeds

Retriever - Golden 3
Shar Pei 1
Dachshund (unspecified) 1
Rottweiler 1
Domestic Shorthair 1
Crossbred Canine/dog 1
Catahoula Leopard Dog 1
Siamese 1

Most Reported Reactions

Disorientation 2
Hypoglycaemia 2
Lethargy (see also Central nervous system depression in 'Neurological') 2
Restlessness 2
Injection site lump 1
Blepharospasm 1
Decreased appetite 1
Hyperglycaemia 1
Weight loss 1
Excessive thirst 1
Disoriented state 1
Other abnormal test result NOS 1

Outcome Breakdown

Recovered/Normal
6 (60.0%)
Ongoing
2 (20.0%)
Outcome Unknown
1 (10.0%)
Euthanized
1 (10.0%)

Ofloxacin Ophthalmic Adverse Event Insights

10 reports name Ofloxacin Ophthalmic; 1 recorded a death outcome (10.0% of reported events, not a population-level mortality rate). Active ingredient: Ofloxacin Ophthalmic. Administration routes: Intraocular, Ophthalmic, Unknown, Topical.

By species: Dog (8 reports), Cat (2 reports). By breed: Retriever - Golden (3), Shar Pei (1), Dachshund (unspecified) (1).

Leading clinical signs: Disorientation (2), Hypoglycaemia (2), Lethargy (see also Central nervous system depression in 'Neurological') (2), Restlessness (2). Outcome, 10 coded reports: Recovered/Normal leads at 60.0%.

Read these counts as reporting volume, not risk: per our methodology, a widely-prescribed drug will rack up more raw FDA reports in a given year than a rarely-used one at an identical true rate, so we recommend comparing within similar-exposure products rather than across the full 2025 catalog.

Source: FDA Center for Veterinary Medicine openFDA Animal & Veterinary Adverse Events (CVM AER) · 2025

Every figure on PlainBreed is rendered directly from FDA openFDA adverse event data, no number is typed in by an editor. This page draws directly on FDA openFDA data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.